Spero Therapeutics reported second quarter 2026 EPS of -$0.16 following FDA approval of Utebzi

Spero Therapeutics reported a net loss of $9.6 million on zero revenue for the second quarter of 2026 as the company transitions its focus toward its new immunology pipeline. During the period, the company achieved a major regulatory milestone with the FDA approval of Utebzi and subsequent non-dilutive financing to support its new lead asset, SP001.

Key Highlights

• Utebzi received FDA approval in June 2026 as the first oral carbapenem for cUTIs, with commercial launch by partner GSK expected by the end of 2026.
• Research and development expenses decreased by 68% year-over-year to $3.4 million, primarily due to the early conclusion of the Utebzi Phase 3 clinical trial.
• Post-quarter financing included a $105 million royalty agreement with HealthCare Royalty Partners, which management expects will extend the cash runway into the second half of 2029.